- Select health products with scientific evidence
The health care products taken need to have certain scientific certification. Health care products with scientific evidence and long-term sale in the market and good reputation are relatively safe and are not prone to safety problems.
- Seek advice from professional doctors, etc
Generally speaking, if parents have questions about what types of health care products their baby can take and how to take them, they can consult professional doctors and nutritionists.
- Stagger the time when taking a variety of health products
When the baby takes two or more different health care products, it should be noted that the taking time should be staggered. Health care products will contain different nutrients, and different nutrients will play a certain role. If the baby needs to take two or more different health products, it is recommended to stagger at least 2 hours.
- Do not take excessive health care products
Do not overdose when taking health care products. Before the baby takes health care products, parents should carefully read the instructions and strictly follow the instructions to give the baby. Sometimes it’s no problem to forget to eat.
Symptoms of heart failure include:
Shortness of breath during activity (most commonly) or rest, especially when you lie flat in bed
A cough that coughs up white phlegm.
Rapid weight gain (it is possible to gain two to three pounds in a day.)
Swelling of ankles, legs and abdomen
Rapid or irregular heartbeat
Other symptoms include nausea, palpitations and chest pain.
Like valve disease, heart failure symptoms may not be related to the degree of heart weakness. You may have many symptoms, but your heart function may be only slightly weakened. Or your heart is badly damaged with few symptoms.
Almost every German clinician will recommend patients to take deep-sea fish oil to enhance their physique and immunity; Almost every dermatologist will recommend taking enough omega-3 to enhance skin vitality and self-healing efficiency of soft tissue; Almost every nutritionist has to admit that fish oil is the most basic, key and effective gold product among all health products.
[taking method] take 1 capsule every day with liquid without chewing.
[baby note] it contains polyunsaturated fatty acids EPA and DHA. One tablet per day contains 1000mg fish oil (180mg EPA, 120mg DHA) and 12mg vitamin E. adequate exercise and healthy diet are an integral part of a healthy lifestyle. An unbalanced diet contains too many saturated fatty acids, animal oil or cholesterol. Polyunsaturated fatty acids, such as omega-3 fatty acids that the body cannot produce by itself, are often not absorbed enough. Omega-3 fatty acids have attracted attention through the phenomenon in Greenland. Eskimos have a simple diet and a high intake of fat, but they usually live a long life and are very healthy. Deep sea fish are the main part of their food, rich in omega-3 fatty acids.
[suitable population] patients with hypertension, high cholesterol, arteriosclerosis and cardiovascular disease. Poor circulation, limb paralysis, sore neck, cold hands and feet. Hyperlipidemia, obesity. Memory loss, Alzheimer’s.
[unsuitable crowd] children and pregnant women!
[ingredient content] omega-3 unsaturated fatty acids (EPA and DHA) contained in 1000mg EPA (eicosapentaenoic acid), 180mg DHA (docosahexaenoic acid), 120mg omega-3 (unsaturated fatty acid) and 300mg vitamin e12mg deep-sea fish oil are important components of brain and nervous system, which help to strengthen brain and intelligence, reduce cholesterol, reduce thrombosis Prevent cardiovascular disease. EPA (eicosapentaenoic acid) anti platelet aggregation, helps to reduce blood viscosity and prevent thrombosis; Regulate blood lipid, enhance cardiovascular and cerebrovascular health and kidney function. DHA (docosahexaenoic acid) is an indispensable material basis for the formation, development and operation of brain cells. It can help improve brain sensitivity and reaction speed, maintain cardiovascular and cerebrovascular health, enhance body immunity, prevent Alzheimer’s disease, etc. Vitamin E prevents oxidation of human cells. Folic acid, vitamins B1, B6 and B12 help to maintain the balance of homocysteine level, so as to reduce the occurrence of cardiovascular and cerebrovascular diseases. Because the higher the homocysteine level, the greater the risk of cardiovascular and cerebrovascular diseases.
[storage method] cool and dry, away from light. Keep out of reach of children.
- Regulate blood lipid, reduce vascular viscosity, increase vascular elasticity and avoid vascular sclerosis.
- Prevent arteriosclerosis, coronary heart disease, hypertension and cold limbs.
- Inhibit blood coagulation and prevent thrombosis.
- Reduce the formation of fat and prevent obesity.
- Prevention of Alzheimer’s disease.
- An important element of maintaining heart health.
In the treatment of ulcerative colitis, Bristol Myers Squibb S1P receptor regulator has obtained new indications
Bristol Myers Squibb (BMS) announced in June that the US FDA approved zeposia (ozanimod) 0.92 mg for the treatment of moderate and severe active ulcerative colitis (UC) in adults. The press release pointed out that this is the first oral S1P receptor modulator approved for the treatment of patients with moderate and severe active UC.
This approval is based on the results of a critical phase 3 clinical trial called true north. Compared with placebo, zeposia in the 10th week of induction treatment (18.4% vs 6.0%; P < 0.0001) and at the 52nd week of maintenance treatment (37.0% vs 18.5%; P < 0.0001) significantly increased the proportion of patients with clinical remission and reached the main end point of the trial. At the same time, zeposia achieved a number of key secondary endpoints, including clinical response, endoscopic improvement, endoscopic histological mucosal improvement and so on.
Ulcerative colitis is a chronic inflammatory bowel disease (IBD), which is characterized by long-term abnormal immune response, resulting in persistent inflammation and ulcer in the mucosa of colon or rectum. Symptoms include bloody stool, severe diarrhea and frequent abdominal pain. Ulcerative colitis has a significant impact on patients’ health-related quality of life, including physical function, social and emotional health, and work ability. Many patients have insufficient or no response to the currently available treatment.
Zeposia (ozanimod) is an oral S1P receptor regulator that binds to S1P receptors 1 and 5 with high affinity. Zeposia reduces the ability of lymphocytes to leave lymph nodes and reduces the number of circulating lymphocytes in peripheral blood. It has been approved by the FDA for the treatment of multiple sclerosis. At present, the mechanism of zeposia in the treatment of ulcerative colitis has not been fully clarified, but it may involve reducing the number of lymphocytes migrating to the inflamed intestinal mucosa.
“Despite a variety of approved therapies, UC patients still have unmet needs and need additional treatment options to help them better manage the disease.” Mr. Adam lenkowsky, head of the U.S. Department of cardiovascular, immunology and oncology of Bristol Myers Squibb, said: “we are very pleased that scientific research in immunology can bring a new treatment option for UC patients with different mechanism of action from existing therapies.”
Recently, Abbott announced that its Amplatzer amulet left atrial appendage occluder has been approved by FDA. The left atrial appendage occluder helps to reduce the risk of stroke in patients with atrial fibrillation, which is one of the most common arrhythmias. The device can immediately close the left atrial appendage (LAA), which is the site where thrombosis may occur in patients with atrial fibrillation (AFib), so as to reduce the risk of stroke.
Amplatzer amulet superior performance
There are abundant comb muscles and muscle trabeculae in the left atrial appendage, and the surface is not smooth, which is easy to make the blood flow produce vortex and slow down. It is the main condition to promote thrombosis, which determines that the left atrial appendage is the prone site of left atrial thrombosis to a certain extent. The effective pumping capacity of the heart in patients with atrial fibrillation may be destroyed, causing blood to accumulate in the left atrial appendage, resulting in an increased risk of coagulation. If blood clots flow to blood vessels, they may enter the brain and cause a stroke. For patients with atrial fibrillation who cannot take blood dilution drugs for a long time, doctors can choose to block or close the left atrial appendage through minimally invasive surgery, such as Abbott’s Amplatzer ™ Amulet ™ The device completely closes the left atrial appendage to reduce the risk of stroke. Abbott said that previous clinical data showed that this product helped to reduce the number of patients with thrombosis by two-thirds every year. In these patients, more than 90% of the thrombosis leading to stroke was caused by the left atrial appendage.
“As the world’s population continues to age, we see a surge in cases of atrial fibrillation, followed by an increased risk of stroke,” said dhanunjaya Lakkireddy, M.D., HCA Midwest health Kansas City Heart Rhythm Institute The FDA approved Abbott’s Amplatzer amulet, which provides doctors with another treatment option to reduce the risk of stroke and avoids the need for hemodilution drugs immediately after surgery. Abbott’s technology is very valuable because these drugs will increase the risk of bleeding. “
Before the approval of this product, the only minimally invasive option for American doctors and their patients to block the left atrial appendage is the solution of sealing the left atrial appendage with a single component. This solution requires hemodilution drugs and additional patient monitoring equipment to ensure the accurate closure of the left atrial appendage. In contrast, Abbott’s Amplatzer amulet uses double occlusion technology to completely and immediately block the left atrial appendage, and patients do not need to use hemodilution drugs after surgery. In addition, the device can also be widely used in anatomical structure surgery, and has the most complete size range of occluder on the market; It can also be recaptured and repositioned to ensure that the device can be placed in the best position. Since the first CE Mark Approval in 2013, the Amplatzer amulet left atrial appendage occluder has been approved for use in more than 80 countries, including Europe, Canada and Australia.
Michael Dale, senior vice president of Abbott’s structural heart business, said: “Amplatzer amulet’s unique double sealing method makes it the first plugging product in the European market. Therefore, today’s FDA approval is an important milestone for Abbott, enabling us to bring this treatment scheme to more American doctors and patients.” This is consistent with our mission and goal and can help people live a healthier and better life. “
Abbott CEO Robert Ford said at the earnings conference call on July 22 that the device obtained the CE mark in 2013, accounting for 50% of the European market, which gave Abbott confidence that it could occupy a place in the U.S. market. According to a recent e-mail statement from Abbott public relations, the American left heart ear market is currently worth $500 million. At present, the product has been approved by FDA, which means that Abbott Amplatzer amulet has become the most powerful competitor of poco’s watchman equipment.
Poco’s watchman products may require patients to require hemodilution therapy for at least three months in the process of postoperative rehabilitation, which virtually increases the risk of bleeding. Abbott said that, in contrast, the design of Amplatzer amulet allows patients to completely skip the postoperative drug treatment stage. The promotion of amulet in the American left atrial appendage market is likely to shake the dominant position of Boko watchman products in the United States. Abbott plans to publish a comprehensive analysis of Amplatzer amulet and watchman at the annual meeting of the European Society of Cardiology later this month.
Investors were very disappointed with Bayer’s performance report released on the 5th. Its share price fell more than 7% on the Frankfurt Stock Exchange, ranking first in the decline of DAX index shares. On the same day, the German chemical pharmaceutical giant also announced its fourth major M & A in a year. This shows that under the negative impact of glyphosate problem, the company is promoting the expansion of its drug research business through acquisition.
Bayer Group, headquartered in Leverkusen, reported on the 5th that affected by the provision for special expenses related to glyphosate litigation (3.9 billion euros), the group had a net loss of 2.33 billion euros in the second quarter. Bayer has provided more than 10 billion euros in reserves for glyphosate litigation last year. So far, the negative impact related to Bayer’s acquisition of Monsanto is expected to basically end.
Bayer’s sales in the first half of the year increased by 1.2% to 23.18 billion euros, of which the sales growth in Asia Pacific region was 4.9%, faster than that in Europe (1.9%) and North America (still negative growth). Bayer also raised its annual sales growth forecast to 6% from the previous 3%.
Bayer Group’s overall loss in the first half of the year was nearly 250 million euros, which was much lower than the loss of 8 billion euros in the same period of the previous year. However, compared with other large German listed companies that frequently released far higher than expected second quarter performance reports recently, Bayer’s performance report on Thursday disappointed investors.
On Thursday, Bayer’s shares on the Frankfurt Stock Exchange plunged 7.60%, not only ranking first in the decline of DAX index shares, but also the highest trading volume of the day. At present, Bayer’s share price is close to 46 euros per share, and its market value is less than 40% of the much smaller Merck group, and only more than half of the German biotechnology company that successfully developed the new crown mRNA vaccine.
Bayer CEO Werner Bowman said on Thursday that the sales momentum of all businesses is expected to remain optimistic. He also highlighted the latest investments in the pharmaceutical sector.
On the same day, Bayer announced that it would acquire American biotechnology company video at a price of up to US $2 billion. The California based company specializes in identifying new binding sites in disease-related proteins and is carrying out preclinical projects based on this technology.
In Bayer’s view, video technology is an ideal supplement to Bayer in the field of pharmaceutical chemistry. The head of Bayer’s pharmaceutical department said that this will enable Bayer to “develop first-class candidate drugs, so as to increase the value of Bayer’s product portfolio”.
It is understood that before Bayer made an offer, video had prepared for an initial public offering. Bayer now pays $1.5 billion directly to its owners and will pay another $500 million based on some development results. The company will be managed as an independent department within Bayer pharmaceutical.
This is Bayer’s fourth research-oriented pharmaceutical acquisition in less than a year. A few weeks ago, the group strengthened its research and development capacity in cancer drugs based on the coupling technology of radioactive atoms and active components molecules by taking over Noria treatment and PSMA treatment companies in the United States.
Last October, Bayer acquired ask biology, an American company specializing in gene therapy, which greatly strengthened its position in the field of gene and cell therapy. In August 2020, Bayer acquired Kandy therapy, a British company, which is studying a drug to treat menopausal symptoms.
German industry experts pointed out that under the shadow of glyphosate problem, Bayer is promoting the expansion of its drug research business through acquisition. Through the recent acquisition, Bayer’s platform strategy is clearer. The group’s goal is to acquire expertise that can be used in a wide range of diseases and to broaden R & D channels on a relatively large scale.
The acquisition of video is in line with this strategy. It is said that the biotechnology company has developed a so-called chemotherapeutic protein technology, which can identify proteins particularly accurately to find possible targets of therapeutic agents.
Jeff Hatfield, the boss of video, said that 90% of disease-related proteins cannot be affected or blocked by therapeutic agents at present. However, with its new technology, hundreds of new attack targets have been identified.
For Bayer, the new round of acquisition is also to reserve the pharmaceutical business after 2024, when its current best-selling anticoagulant xarelto and ophthalmic drug eylea will lose patent protection. The acquisition aims to provide a basis for extensive renewal and expansion of the scope of drugs over the next five years.
Recently, the company’s drug kerendia for renal failure was approved in the United States. The launch of the new anti-cancer drug nubeqa is also progressing smoothly, exceeding expectations. In the first half of 2021, Bayer Group’s drug sales increased by 3.8% to 8.86 billion euros, of which the growth rate in the second quarter reached 12.1%. This puts Bayer back in the middle of the industry.
Previously, many pharmaceutical giants had great interest in the booming field of cell therapy and gene therapy, but they were plagued by a common challenge: how to manufacture these therapies quickly and cheaply?
Last year, Novartis said that Japanese regulators had approved its foundation for biomedical research and innovation in Kobe to commercialize the production of kymriah, making it the first market-oriented factory in Asia to produce this next-generation anti-cancer therapy.
Novartis has established another factory in Stein, Switzerland and recruited 450 new employees to produce this therapy. Kobe’s factory will increase kymriah’s global production footprint. Novartis also commercially produces kymriah in factories in Morris plain, New Jersey and Les Ulis, France, while commercially producing kymriah in the contract manufacturing plant of Fraunhofer Institute of cell therapy and immunology, Leipzig, Germany.
According to a statement, Novartis also plans to produce the therapy at cell therapies in Australia and cellular biomedicine group in China. Recently, the FDA also approved the expansion of Novartis Morris plain plant.
A Novartis spokesman did not say how much capacity the Kobe plant would add to kymriah’s global footprint, but he pointed out that the company had more than tripled kymriah’s capacity in the past year. As logistics challenges have hindered the promotion of kymriah, Novartis hopes to rapidly expand the geographical footprint of this therapy.
Novartis opened a bottleneck by starting the Stein plant in Switzerland to provide tailored cell therapy for European patients. Previously, European patients needed two transatlantic flights to the company’s only factory in Morris plain, USA.
Kymriah was originally approved by FDA in August 2017 for the treatment of recurrent or refractory (R / R) B-cell acute lymphoblastic leukemia (all), making it the first car-t approved in the United States for the treatment of any indication. Novartis subsequently obtained kymriah’s approval for the treatment of B-cell lymphoma in May 2018 and is seeking the third indication for the treatment of follicular lymphoma. The company is expected to submit an application in 2021.
At the time of opening, the Stein plant in Switzerland employed 185 employees, many of whom worked in Novartis’s “traditional chemical and pharmaceutical manufacturing” plants in Basel, schweizerhalle and Stein, Switzerland. Novartis plans to increase the number of employees to 450 within three years and invest US $90.6 million.
With the approval of new cell and gene therapies expected to gradually increase in the next few years, pharmaceutical manufacturers are paying huge investments to overcome the expected manufacturing crisis.
Yescarta, a cell therapy company from Geely De’s kite, is the second car-t therapy approved by FDA. The company has also been expanding rapidly, including the construction of a long-awaited 117000 square foot factory in segro Amsterdam Airport Industrial Zone (SPAA) in June 2020.
According to chuck calderaro, head of global technology operation of kite, this latest facility is Geely De’s “next step” in upgrading the global manufacturing industry of yescarta, because the plant will be able to meet the needs of 4000 patients for yescarta every year.
On August 23, Bristol Myers Squibb $BMY announced that orencia’s listing application for the prevention of moderate / severe acute graft-versus-host disease (aGVHD) in patients over 6 years old receiving unrelated hematopoietic stem cell transplantation was granted priority review qualification by FDA.
Hematopoietic stem cell transplantation is an effective method for the treatment of invasive leukemia and other malignant hematoma. However, GVHD occurs when donor T cells recognize the patient’s healthy cells as foreign objects and begin to attack. This activation of T cells can lead to severe immune-mediated tissue damage in the host. Skin, liver and gastrointestinal tract are the most common targets. Orencia is a fusion protein composed of CTLA-4 and FC, which can bind and inhibit protein targets involved in CO stimulation, so as to inhibit T cell activation.